MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/70/0.1/20.12.24

MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/70/0.1/20.12.24 Share Price

DE000MB3F213

Delayed Börse Stuttgart 19:42:10 26/06/2024 BST
1.16 ^EUR	-1.69%

Current month	+9.43%
1 month	+1.75%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/70/0.1/20.12.24

Latest news about ASTRAZENECA PLC

Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology	11-30	PR
New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy	14/04/23	PR
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research	27/10/22	PR
Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer	13/05/22	PR

More news

Quotes 5-day view

Date	Price	Change
26/06/24	1.16	-1.69%
25/06/24	1.18	+1.72%
24/06/24	1.16	+1.75%
21/06/24	1.14	+5.56%
20/06/24	1.08	+0.93%

Delayed Quote Börse Stuttgart

Last update June 26, 2024 at 07:42 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	Morgan Stanley
WKN	MB3F21
ISIN	DE000MB3F213
Date issued	08/02/2023
Strike	70 $
Maturity	20/12/2024 (177 Days)
Parity	10 : 1
Emission price	0.77 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.36 €
Lowest since issue	0.19 €
Delta	0.78x
Omega	5.097
Premium	3.73x
Gearing	6.58x
Moneyness	1.130
Difference Strike	-9.08 $
Difference Strike %	-12.97%
Spread	0.03 €
Spread %	2.63%
Theoretical value	1.145
Implied Volatility	29.73 %
Total Loss Probability	28.92 %
Intrinsic value	0.8496
Present value	0.2954
Break even	82.24 €
Theta	-0.01x
Vega	0.02x
Rho	0.02x

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: AstraZeneca PLC

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

158.5 USD

Average target price

174.4 USD

Spread / Average Target

+10.04%

Consensus